The state’s Biotechnology Task Force released a 44-page report of recommendations to the state that could help New Jersey reinvigorate its life sciences sector.
Many of the themes from the report echo comments from the Biotechnology Innovation Organization’s annual conference in Boston recently.
Wed, Jun 20, 2018 at 1:00 PM
Come meet our Spring Cohort of next generation technology ventures in: AR/ VR, Smart Parking, Intelligent Buildings, Mobile Wallet, Multi-modal Transport, Cyber Security, that are changing the way we design, build, and operate cities!
Paid Public Parking is available in the garage beneath the Virginia Tech Research Centre. Garage entrance is off 9th Street at the corner of Glebe Road.
The Rare Genomics (RG) Institute is delighted to announce the winners of the 2017 BeHEARD (Helping Empower and Accelerate Research Discoveries) science challenge, a global competition that offers rare disease researchers, who traditionally have difficulty attracting funding, grants of the latest life science innovations and technologies. This unique crowdsourced biotechnology competition allows companies to contribute their technology to make a difference for the rare disease community.
Baltimore-based Insilico Medicine landed a new strategic investment from Chinese biotech company WuXi AppTec.
The amount of the funding was not disclosed, but the investment also includes a strategic partnership between Insilico and WuXi, which specializes in contract research for the pharmaceutical and medical device industries.
If indeed “innovation distinguishes between a leader and a follower,” as Steve Jobs wrote in 2001, then this year’s Top 10 Under 40 are well on the way to becoming leaders in biopharma research and business.
United Therapeutics Corporation (NASDAQ: UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), today announced that the use of XVIVO’s ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics’ public benefit corporation subsidiary Lung Biotechnology PBC.
You know already about the promise for CRISPR-Cas9 — it might revolutionize fields from medicine to agriculture.
It might also eventually cause tumors.
So far, the digital revolution has mostly been a disappointment in health care. Doctors stare at their screens instead of us. Specialists and emergency rooms still don’t have all our records.
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its NSI-566 human neural stem cell line as a candidate therapeutic for severe Traumatic Brain Injury (TBI).
Maryland Technology Development Corp. is launching a new fund that will offer early stage investments of $50,000 to startups that may be overlooked by other funding organizations.
